EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise

Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.

MT1805_Eiffel Tower_710380270 _1200
EuroPCR 2018 is held in Paris, France between May 22-25

Tendyne, the mitral valve replacement technology that Abbott Laboratories Inc. acquired three years ago, has potential to successfully treat patients with severe mitral regurgitation, according to early follow-up data presented May 23 at EuroPCR in Paris.

The results from a single-arm, multicentre global study to support the CE mark of Tendyne were presented at EuroPCR by...

More from Cardiology

More from Device Area